tradmap

ADIL Earnings Adial Pharmaceuticals, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$68 -$34 $0 2021 2022 2023 2024 2025
EPS
Net income (annual)
-$19M -$10M $0 2017 2018 2019 2020 2021 2022 2023 2024 2025
Net income
Return on equity (annual)
-554% -220% 114% 0% 2017 2018 2019 2020 2021 2022 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$18 -$9 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Net income (quarterly)
-$52M -$26M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-106% 15% 135% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–21 of 21
Q2 20262026-06-30-17.972026-08-1410-Q
Q1 20262026-03-31-1.482026-05-0810-Q
FY 20252025-12-31-11.932026-03-0510-K
Q3 20252025-09-30-0.452025-11-1310-Q
Q2 20262025-06-30-12.192026-08-1410-Q
Q1 20262025-03-31-8.522026-05-0810-Q
FY 20252024-12-31-68.012026-03-0510-K
Q3 20252024-09-30-2.572025-11-1310-Q
Q2 20252024-06-30-2.502025-08-1310-Q
Q1 20252024-03-31-2.192025-05-1410-Q
FY 20242023-12-31-3.602025-03-0410-K
Q3 20242023-09-30-2.862024-11-1310-Q
Q2 20242023-06-30-1.662024-08-1310-Q
Q1 20232023-03-31-0.112023-05-1210-Q
FY 20232022-12-31-12.712024-04-0110-K
Q3 20232022-09-30-9.942023-11-1410-Q
Q2 20232022-06-30-7.242023-08-2110-Q
Q1 20232022-03-31-0.132023-05-1210-Q
FY 20222021-12-31-1.042023-03-3010-K
Q3 20222021-09-30-0.762022-11-1410-Q
Q2 20222021-06-30-0.552022-08-1510-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.